Journals / Mucosa / 2019 / Cilt: 2 - Sayı: 4

Human papillomavirus vaccination: review of the current evidence

İnsan papilloma virüs aşısı: Güncel kanıtların gözden geçirilmesi

Journal
Mucosa
Pages
86–94
Publication Date
2019-12-29
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We need more time to obtain follow-up data for the real-world efficacy, and more research in HPV vaccination.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Human papillomaviruses (HPV) can cause numerous cancers in males and females, including anogenital cancers.
📊
Key Findings & Data:HPV vaccines have been a controversial issue since the first vaccine was recommended to prevent cervical cancer in 2006.
💡
Conclusion & Impact:We need more time to obtain follow-up data for the real-world efficacy, and more research in HPV vaccination.
🔬Design:Research Article
📍Scope:2006 Verileri
⚙️Variables:Aşılama · insan papilloma virusleri · HPV aşısı

Abstract

Human papillomaviruses (HPV) can cause numerous cancers in males and females, including anogenital cancers. Cervical cancer, which is mainly caused by HPV, is one of the most preventable type of cancers. Since the understanding of the etiological association between HPV and cervical cancer, three HPV vaccines have been developed to date. HPV vaccines have been a controversial issue since the first vaccine was recommended to prevent cervical cancer in 2006. Although there are still ongoing controversial topics about HPV vaccines, such as efficacy in HPV-associated cancers, usage in HPV infected individuals and males, these vaccines present an opportunity for HPV-associated precancerous lesions prevention. World Health Organization (WHO) recognizes HPV-associated diseases as global health problems, and recommends that routine HPV vaccination should be included in national immunization programs. While some high-income countries have relatively high uptake of HPV vaccination rates, the low income countries are lagging in the introduction of HPV vaccine. In Turkey, the available vaccines are not in routine immunization schedule. The HPV vaccines are not only need to be more effective, but also be cheap and affordable for everyone in order to increase and sustain introductions of HPV vaccine in low-income and middle-income countries. We need more time to obtain follow-up data for the real-world efficacy, and more research in HPV vaccination.

Özet

İnsan papilloma virüsleri (HPV), erkeklerde ve kadınlarda, anogenital kanserler dâhil, çok sayıda kansere neden olabilir. Ağırlıklı olarak HPV’nin neden olduğu serviks kanseri, en önlenebilir kanser türlerinden biridir. HPV ve serviks kanseri arasındaki etiyolojik ilişkinin anlaşılmasından bu yana, bugüne kadar üç HPV aşısı geliştirilmiştir. HPV aşıları, 2006’da serviks kanserinin önlenmesi için önerilen ilk aşı ortaya çıktığından beri tartışmalı bir konu olmuştur. Her ne kadar aşıların HPV-ilişkili kanserlerdeki etkinliği, erkeklerde ve HPV ile enfekte bireylerdeki kullanımı gibi konularda tartışmalar hala devam etse de, HPV aşıları, HPV ilişkili prekanseröz lezyonların önlenmesi konusunda bir fırsat sunmaktadır. Dünya Sağlık Örgütü, HPV ile ilişkili hastalıkları küresel sağlık sorunları olarak kabul etmekte ve rutin HPV aşılarının ulusal aşılama programlarına dahil edilmesi gerektiğini önermektedir. Bazı yüksek gelirli ülkeler nispeten yüksek oranda HPV aşılama oranlarına sahipken, düşük gelirli ülkeler HPV aşısına ulaşma konusunda gecikmektedir. Türkiye’de mevcut HPV aşıları ulusal aşılama programında değildir. HPV aşılarının, düşük gelirli ve orta gelirli ülkelere ulaşımını artırmak ve sürdürmek için daha etkili olmasının ötesinde herkes için ucuz ve uygun olması da gerekir. Gerçek dünyadaki etkinliği açısından takip verilerine, bunun için de daha fazla zamana ve HPV aşıları ile ilgili daha çok araştırmaya ihtiyacımız vardır.

🔖

Cite This Article

ÖZÇELİK, S., KILIC, F. A. (2019). Human papillomavirus vaccination: review of the current evidence. Mucosa, Cilt: 2 - Sayı: 4, 86–94. https://ajindex.com/articles/840041

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Plummer M, Schiffman M, Castle PE, Maucort-Boulch D, Wheeler CM. A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. The J Infect Dis 2007;195:1582-9
  2. Saraiya M, Unger ER, Thompson TD, et al. US assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines. J Natl Cancer Inst 2015;107:86
  3. Viens LJ, Henley SJ, Watson M, et al. Human papillomavirus-associated cancers-united states, 2008-2012. MMWR Morb Mortal Wkly Rep 2016;65:661-6
  4. Villa LL, Costa RL, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005;6:271-8
  5. Crowe E, Pandeya N, Brotherton JM, et al. Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case-control study nested within a population based screening programme in Australia. BMJ 2014;348:1458
  6. McNamara M, Batur P, Walsh JME, Johnson KM. HPV Update: Vaccination, screening, and associated disease. J Gen Intern Med 2016;31:1360-6
  7. Giuliano AR, Palefsky JM, Goldstone S, et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med 2011;364:401-11
  8. Bogaards JA, Wallinga J, Brakenhoff RH, Meijer CJ, Berkhof J. Direct benefit of vaccinating boys along with girls against oncogenic human papillomavirus: bayesian evidence synthesis. BMJ 2015;350:2016
  9. Elfstrom KM, Lazzarato F, Franceschi S, Dillner J, Baussano I. Human papillomavirus vaccination of boys and extended catch-up vaccination: Effects on the resilience of programs. J Infect Dis 2016;213:199-205
  10. Saslow D, Castle PE, Cox JT, et al. American cancer society guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin 2007;57:7-28
  11. Petrosky E, Bocchini JA, Jr., Hariri S, et al. Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep 2015;64:300-4
  12. Meites E, Szilagyi PG, Chesson HW, Unger ER, Romero JR, Markowitz LE. Human papillomavirus vaccination for adults: Updated recommendations of the advisory committee on immunization practices. MMWR Mor